UBS Global Healthcare Conference - INTEGRA LIFESCIENCES HOLDINGS CORP

Financial Performance:

• Specialized Surgery division grew 4% YoY; Neurosurgery sub-segment grew 6.5% (including a $7M Q3 headwind from the Cincinnati flood).
• International Specialty business grew high single digits, driven by restored supply availability and "pull-through" demand.
• Tissue Reconstruction saw sequential growth in Integra Skin but underperformed relative to forecasts due to past supply constraints and competitive share loss; Primatrix (relaunched) is recovering >50% of pre-recall revenue.
• Gross margins are projected flat for the year, a significant stabilization compared to the declining trend of prior years.
• Free Cash Flow (FCF) projected at $130–$140 million for the current year, a rebound from $25 million in 2024 and a significant recovery from the 2023 level of $73 million.
• Earnings Per Share (EPS) expected to grow ~5% after double-digit declines in the previous two years.

Guidance and Future Outlook:

• Cincinnati flood impact forecasted at $15–$20 million for Q4; full operational recovery for the Mayfield product line expected mid-2027 due to specialized equipment lead times.
• Supply chain remediation plan is on track, with all portfolio products expected to be back on the market by 2027.
• Company aims to resume high-single-digit international growth rates once fully operational.
• PMA (Premarket Approval) for Surgiman (breast reconstruction) and Durazor (implant-based) expected in 2027 to expand product labels.
• Management anticipates returning to offensive commercial strategies post-supply stabilization, focusing on underpenetrated international markets.

Business Segments and Product Lines:

• Specialty Surgery: Dominant market position (ranked #1 or #2 in most sub-segments); growth driven by durable demand for non-elective procedures (trauma/acute) and improved supply reliability.
• Tissue Reconstruction: 90% of business is inpatient-based; 10% outpatient. Portfolio includes Integra Skin, Primatrix, Durazorb, and Surgimen.
• Strategic Restructuring: Creation of a Chief Commercial Officer (CCO) role to consolidate commercial/contracting activities for better GPO negotiation and enterprise-wide value proposition.
• Innovation: Focus on new product introductions in catheters, tissue ablation, and expanding breast reconstruction indications via PMA approvals.

Market and Competitive Landscape:

• Market Trends: Demand driven by clinically necessary procedures with stable volumes; less sensitive to elective care cuts.
• Competition: Competes with large MedTech conglomerates in niche spaces; advantages include deep surgeon relationships, established clinical evidence, and broad portfolio scale.
• International: China market is attractive for volume despite VBP (Value-Based Procurement) pressures; local manufacturing facility operational to mitigate tariffs and improve margin dynamics.
• Consolidation: Fragmented Wound Union & Necrotizing Wound (WUNC) market expected to see consolidation or vendor exit due to fixed reimbursement rates and lack of clinical evidence among smaller players.

Risks and Challenges:

• Cincinnati Flood: Major disruption to Mayfield line and fixed assets; full remediation timeline extends to mid-2027.
• Macroeconomics: Exposure to material inflation, wage increases, freight costs, interest rates, and tariffs.
• Regulatory/Policy: Pressure from government payers (e.g., CMS in US, VBP in China); evolving reimbursement structures impacting pricing power in outpatient settings.
• Competitive Retention: Risk of losing share in wound reconstruction to new entrants during periods of supply constraint.

Management Commentary and Tone:

• Tone is confident yet realistic, acknowledging the "execution discount" on the stock while highlighting the inflection point in operational stability.
• Emphasis on "going on offense" commercially now that supply chain resilience is restored.
• Management highlighted significant progress in fixing broken operations, with gross margins stabilizing and FCF recovering significantly without requiring aggressive price hikes (only ~1% price inflation captured).
• CFO noted that while the "fix" phase is major, a clear runway for profitable growth is emerging.

Analyst Questions and Answers:

• CCO Role Strategy: Explained as a move to consolidate enterprise sales for GPOs, moving beyond divisional silos to leverage the full portfolio for broader contracting and supply chain discussions.
• Market Share Leverage: Confirmed ability to leverage dominant neurosurgery positions to support growth in fragmented markets via portfolio integration.
• Supply Chain Resilience: Discussed the shift from crisis management to offensive strategy; highlighted 50+ products relaunched and remaining products to be added by 2027.
• China Market Dynamics: Addressed VBP risks, noting neurosurgery has faced less pressure than cardiovascular; local manufacturing helps mitigate tariffs and maintain access.
• Investment Prioritization: Explained balancing capital allocation between Tissue Reconstruction and Specialty Surgery based on innovation timelines, ROI, and accretive growth potential.

Other Key Points:

• Capital Structure: Recently refinanced debt to extend maturities; 75% of capital structure is fixed through 2027, providing interest rate stability and flexibility for future capital markets access.
• Customer Dynamics: Surgeons prioritize clinical evidence, supplier reliability, and economic value; Integra's portfolio is designed to address these needs directly.
• Personnel: High retention of sales representatives maintained despite disruption, preserving critical surgeon relationships.
• Operational Efficiency: Management views cost efficiency and supply improvements as the primary levers to offset inflation, rather than relying solely on price increases.